Anaheim Ducks Captain Ryan Getzlaf to Host 5th Annual Getzlaf Golf Shootout to Benefit CureDuchenne
Newport Beach, Calif.
Newport Beach, Calif., May 27, 2015 – The 5th Annual Getzlaf Golf Shootout benefiting CureDuchenne will be held September 12 at Sutra Lounge in Costa Mesa, Calif. and September 13 at the Monarch Beach Golf Links in Dana Point, Calif. Hosted by Ryan Getzlaf, captain of the Anaheim Ducks, the Getzlaf Golf Shootout is a two-day charity golf event that brings together athletes, celebrities and community leaders teaming up in support of CureDuchenne.
Each foursome includes a professional athlete or celebrity as a fifth player. Current and former Anaheim Ducks teammates and coaches including Bruce Boudreau, Scott Neidermayer, Teemu Selanne, Ryan Kesler, Corey Perry, Andrew Cogliano, Frederik Andersen, Mark Fistric, Tim Jackman, Clayton Stoner, Brian Sutherby, Dany Heatley, Kent Huskins, Bob Murray, Andy Sutton and Emerson Etem have played in past tournaments.
CureDuchenne is a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. Duchenne is a progressive muscle disease that impacts one in every 3,500 boys. Boys are usually diagnosed at age 5, are in a wheelchair by 12 and most don’t survive their mid-20s. Currently there is no cure for Duchenne. Proceeds of the event will fund impactful research to find a cure for Duchenne.
Getzlaf Golf Shootout sponsors include Patriot Environmental Services, Bauer, CNC Motors, Gateway One Lending, Fullmer Construction, Mark Beamish Waterproofing and The Sports Corporation.
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have advanced into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.